Red light therapy for gynaecomastia is increasingly promoted by wellness clinics and device manufacturers, yet the evidence base remains critically limited. Gynaecomastia — the benign enlargement of glandular breast tissue in males — affects an estimated 30–60% of men at some point in their lifetime and can cause significant physical discomfort and psychological distress. This article examines what red light therapy is, how it is proposed to work on breast tissue, what the current clinical evidence shows, and how it compares with NHS- and NICE-recommended treatments. It also outlines when to seek medical advice and what red flag symptoms should prompt urgent GP review.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an oestrogen–androgen imbalance; it affects 30–60% of males and can result from medications, medical conditions, or physiological changes.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting in a firm or rubbery swelling beneath one or both nipples. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular proliferation and is commonly associated with obesity. Gynaecomastia is surprisingly common, affecting an estimated 30–60% of males at some point during their lifetime, with peaks occurring during neonatal development, puberty, and older adulthood.

The underlying cause is typically an imbalance between oestrogen and androgen activity within breast tissue. Oestrogens stimulate ductal and stromal growth, whilst androgens — primarily testosterone — counteract this effect. When this balance is disrupted, glandular proliferation can occur. It is also worth noting that obesity increases peripheral aromatisation of androgens to oestrogens, which may contribute to true gynaecomastia as well as fatty tissue deposition.

Common causes include:

• Physiological changes during puberty or ageing

• Medications such as spironolactone, cimetidine, anabolic steroids, anti-androgens (including finasteride and bicalutamide), some antiretrovirals, certain calcium-channel blockers, and some antipsychotics

• Medical conditions including hypogonadism, hyperthyroidism, liver cirrhosis, chronic kidney disease, Klinefelter syndrome, and testicular or hCG-secreting tumours

• Recreational substances: heavy alcohol use (partly via alcohol-related liver disease, which impairs oestrogen metabolism) and cannabis use have been associated with gynaecomastia, though the evidence is largely associative rather than proven causal

• Idiopathic causes, where no clear trigger is identified

In many adolescent males, pubertal gynaecomastia resolves spontaneously within one to two years without intervention. However, persistent or symptomatic cases — particularly those causing pain, tenderness, or psychological distress — warrant clinical evaluation. It is important to distinguish gynaecomastia from rarer but more serious conditions such as male breast cancer, which typically presents as a unilateral, eccentric, hard mass, often with associated skin or nipple changes. Any such presentation should prompt urgent medical review.

Further information is available from the NHS (Enlarged male breasts: gynaecomastia) and the NICE Clinical Knowledge Summary (CKS): Gynaecomastia.

How Red Light Therapy Works on Breast Tissue

Red light therapy stimulates mitochondrial energy production and modulates inflammation, but there is no robust evidence it can reduce glandular breast tissue, which is fibrous and unlikely to regress with photobiomodulation.

Red light therapy (RLT), also referred to as photobiomodulation (PBM) or low-level laser therapy (LLLT), involves the application of low-wavelength red or near-infrared light — typically in the range of 630–850 nanometres — to body tissues. The proposed mechanism centres on the absorption of photons by mitochondrial chromophores, particularly cytochrome c oxidase, which is thought to enhance cellular energy production (ATP synthesis), reduce oxidative stress, and modulate inflammatory pathways.

Proponents suggest that these cellular effects may translate into a range of tissue-level outcomes, including:

• Reduced localised inflammation and oedema

• Stimulation of collagen synthesis and tissue remodelling

• Improved lymphatic drainage and microcirculation (hypothesised; not robustly demonstrated in clinical studies)

• Modulation of adipocyte (fat cell) activity, potentially influencing body contouring (speculative; evidence is limited and inconsistent)

These proposed tissue-level effects remain largely hypothetical in many contexts and should not be taken as established clinical outcomes. In the context of breast tissue specifically, some commercial providers claim that RLT can reduce glandular or fatty tissue volume, improve skin laxity, or alleviate tenderness. These claims are largely extrapolated from studies in other tissue types — such as wound healing, musculoskeletal pain, and cosmetic fat reduction — rather than from direct research on male breast tissue.

It is worth noting that glandular gynaecomastia involves fibrous stromal and ductal tissue, which behaves differently from adipose tissue. Established fibrotic glandular tissue is very unlikely to regress with PBM, and the biological plausibility of RLT meaningfully reducing such tissue is not supported by robust mechanistic evidence. Any perceived benefit in pseudogynaecomastia (fatty tissue) may be more plausible in theory, though still unproven in clinical practice.

Patients should also be aware that RLT should not be applied directly over any area of suspected malignancy, and direct ocular exposure must be avoided (see the Risks and Safety section below). Patients should approach commercial claims in this area with appropriate caution.

Current Evidence for Red Light Therapy in Gynaecomastia

There are no randomised controlled trials, systematic reviews, or NICE recommendations supporting red light therapy for gynaecomastia; existing body-contouring studies are methodologically weak and not applicable to male glandular tissue.

At present, there is no robust clinical evidence specifically evaluating red light therapy as a treatment for gynaecomastia in males. A review of the published literature reveals an absence of randomised controlled trials (RCTs), systematic reviews, or high-quality observational studies examining RLT's efficacy or safety in this specific indication. We are not aware of any UKCA/CE-marked medical device with an intended use of treating gynaecomastia, and no NICE or NHS recommendations exist for RLT in this indication.

Some small studies and pilot trials have explored low-level laser therapy for body contouring and subcutaneous fat reduction, with modest and inconsistent results. However, these studies typically involve female participants, target adipose tissue rather than glandular tissue, and use highly variable treatment protocols, making generalisation difficult. There is no established link between these findings and the management of gynaecomastia.

The broader field of photobiomodulation research is hampered by significant methodological limitations, including:

• Small sample sizes and lack of blinding

• Inconsistent treatment parameters (wavelength, power density, duration)

• Short follow-up periods and absence of validated outcome measures

• Publication bias favouring positive results

In the UK, medical devices must carry UKCA or CE marking for their intended use; the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the device regulatory framework but does not grant product 'approvals' or 'clearances' in the way that medicines are licensed. The European Medicines Agency (EMA) has no role in the approval of medical devices. Patients encountering marketing claims suggesting regulatory endorsement of RLT for gynaecomastia should be encouraged to seek evidence-based medical advice before committing to such treatments, which can carry significant financial cost.

NICE Evidence Search and the NICE CKS: Gynaecomastia provide further guidance on evidence-based management options.

NHS and NICE Guidance on Gynaecomastia Treatments

NICE CKS guidance recommends watchful waiting for physiological gynaecomastia, off-label tamoxifen for symptomatic cases, and subcutaneous mastectomy for established fibrotic disease; red light therapy features in no NHS or NICE pathway.

The NHS and the NICE Clinical Knowledge Summary (CKS): Gynaecomastia provide clear, evidence-based guidance on the assessment and management of gynaecomastia. There is no standalone NICE guideline (NG) specific to gynaecomastia; the NICE CKS is the primary UK reference for primary care management. Initial evaluation typically involves a thorough clinical history, physical examination, and targeted investigations to identify any underlying cause. These may include blood tests assessing testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, beta-human chorionic gonadotrophin (beta-hCG), thyroid function, liver function, and renal function, alongside a medication review. Formal testicular examination is an important part of the clinical assessment, and testicular ultrasound may be arranged where a testicular cause is suspected.

For the majority of cases — particularly physiological gynaecomastia in adolescents — watchful waiting is the recommended first-line approach, given the high rate of spontaneous resolution. Where an underlying cause is identified, addressing it directly (for example, withdrawing a causative medication or treating an endocrine disorder) often leads to improvement.

For persistent or symptomatic gynaecomastia, management options consistent with NICE CKS guidance include:

• Pharmacological treatment: Tamoxifen (an oestrogen receptor modulator) may be considered off-label for early or painful gynaecomastia; typical UK practice is 10–20 mg once daily for up to three to six months, though this should be guided by a clinician and the BNF. Danazol has also been used off-label but is rarely recommended due to its androgenic adverse effects and less favourable tolerability profile. Neither tamoxifen nor danazol is licensed specifically for gynaecomastia in the UK. Aromatase inhibitors are generally not recommended for idiopathic gynaecomastia.

• Surgical intervention: Subcutaneous mastectomy or liposuction-assisted surgery is the definitive treatment for established, fibrotic gynaecomastia. NHS access to surgery varies by Integrated Care Board (ICB) policy and may require prior approval; purely cosmetic indications are often not funded.

• Psychological support: Referral for counselling or psychological support may be appropriate where body image distress is significant.

Notably, red light therapy does not feature in any current NHS pathway or NICE guidance for gynaecomastia. Patients seeking treatment should be directed towards evidence-based options through their GP or an NHS endocrinology or surgical service.

See also: BNF entries for tamoxifen and danazol; emc SmPCs for tamoxifen and danazol; NHS website: Enlarged male breasts (gynaecomastia).

Risks, Limitations, and Safety Considerations

Red light therapy risks include retinal damage, skin reactions, and thermal burns; it must not be used over suspected malignancy, and pursuing it may delay diagnosis of a serious underlying condition.

Red light therapy is generally considered to have a favourable safety profile when used appropriately, and serious adverse events are uncommon in the published literature. However, the regulatory landscape for light-based devices in the UK is important to understand. If marketed as a medical device with a medical claim, a product should carry UKCA or CE marking for its intended use; the MHRA oversees this framework but does not grant consumer 'clearance' or pre-market approval. Cosmetic and wellness devices that make no medical claims are regulated under general product safety law, overseen by the Office for Product Safety and Standards (OPSS) and local authorities. Patients should verify that any device or clinic they use complies with relevant UK regulations.

Known and potential risks associated with red light therapy include:

• Eye injury: Direct or prolonged exposure to red or near-infrared light can cause retinal damage; appropriate protective eyewear must be worn at all times during treatment

• Skin reactions: Mild erythema, warmth, or temporary skin irritation may occur, particularly in individuals with photosensitive conditions or those taking photosensitising medications (including certain antibiotics and NSAIDs)

• Thermal injury: Higher-powered devices carry a risk of burns if used incorrectly or for excessive durations

• Use over suspected malignancy: RLT should not be applied directly over any area where malignancy is suspected; manufacturer instructions for use (IFUs) commonly also advise against direct application over the thyroid gland or testes

Beyond direct safety concerns, a significant limitation of pursuing red light therapy for gynaecomastia is the opportunity cost — both financial and medical. Commercial RLT sessions can be costly, and reliance on an unproven treatment may delay appropriate diagnosis and management of an underlying condition. In some cases, gynaecomastia is a marker of a serious systemic illness, and deferring medical evaluation in favour of alternative therapies carries genuine clinical risk.

Patients with a personal or family history of breast cancer, or those with rapidly progressive or unilateral breast changes, should not delay seeking medical assessment in favour of any unproven intervention, including red light therapy.

If you experience an adverse reaction to a device or suspect a device-related incident, this can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

When to Speak to a GP About Gynaecomastia

A GP should be consulted for unilateral, hard, or rapidly growing breast swelling, nipple discharge, persistent pain, or psychological distress; red flag features warrant urgent referral via the two-week-wait suspected cancer pathway.

Many men and adolescent boys feel embarrassed or reluctant to seek medical advice about gynaecomastia, yet timely assessment is important both to exclude serious underlying causes and to access appropriate treatment. A GP consultation is recommended in any of the following circumstances:

• Breast swelling that is unilateral, hard, irregular, or rapidly growing, which may warrant urgent investigation to exclude male breast cancer

• Nipple discharge, skin tethering, or nipple inversion, which are potential red flag features

• Significant pain or tenderness that is affecting daily activities or quality of life

• Gynaecomastia persisting beyond two years in adolescents, or new-onset enlargement in adult males without an obvious cause

• Associated symptoms such as unexplained weight loss, fatigue, testicular changes, or features of liver or thyroid disease

• Psychological distress, including anxiety, low self-esteem, or avoidance of social or physical activities due to breast appearance

Where red flag features are present — such as a hard, unilateral, or rapidly changing breast mass, nipple discharge, or skin changes — the GP should consider urgent referral to a breast clinic via the two-week-wait suspected cancer pathway, in line with NICE NG12: Suspected cancer: recognition and referral.

During the consultation, the GP will take a detailed history — including a full medication and supplement review — perform a clinical examination including testicular assessment, and arrange appropriate investigations. These may include blood tests (testosterone, LH, FSH, oestradiol, prolactin, beta-hCG, thyroid, liver, and renal function) and, where indicated, testicular ultrasound. Referral to an endocrinologist, urologist, or breast surgeon may follow depending on findings. In secondary care, specialist imaging such as breast ultrasound or mammography may be arranged where malignancy is suspected.

It is entirely reasonable to discuss complementary or alternative approaches with a GP, including red light therapy. A good clinician will provide balanced, non-judgemental guidance and help patients weigh the available evidence. However, patients are encouraged not to self-treat with unproven therapies as a substitute for medical assessment, particularly where red flag features are present. Early, evidence-based intervention offers the best outcomes for both the physical and psychological aspects of gynaecomastia.

Key references: NICE NG12: Suspected cancer: recognition and referral; NICE CKS: Gynaecomastia; NHS website: Enlarged male breasts (gynaecomastia).

Frequently Asked Questions